MORE►
Nacuity Pharmaceuticals
Fort Worth-based Nacuity Pharmaceuticals won a patent this week for a method of treating retinitis pigmentosa with an oral antioxidant drug. This illustration shows pigment deposits in the retina, a sign of the genetic eye disease. [Illustration: AdobeStock]
Patented: Nacuity’s Vision-Loss Drug Method and 124 More Inventions Across North Texas
by Dave Head | Jul 29, 2026
Dallas-Fort Worth ranked No. 9 for patent activity out of 250 metros for the week of June 30 with a total of 125 patents granted.
by Lance Murray |
Apr 19, 2024
Emmett T. Cunningham is a senior partner at HealthQuest Capital Management and co-founder and executive chairman of Eyconis, a spinout of Ascendis Pharma.
MORE►
by Kevin Cummings |
Jun 17, 2022
What companies are finding funding or having a big exit? From startup investments to grants and acquisitions, Dallas Innovates tracks what’s happening in North Texas money....
MORE►
by Kevin Cummings |
Jun 15, 2022
Nacuity Pharmaceuticals focuses on ocular diseases caused by oxidative stress in the retina, including age-related macular degeneration, glaucoma, and diabetic retinopathy. The $16.5M funding, led by the Foundation Fighting Blindness, will help advance two Nacuity clinical trials.
“This funding will help further our mission to develop a breakthrough treatment for retinitis pigmentosa and other serious blinding and chronic diseases," said Nacuity Chairman, CEO, and Co-founder Halden Conner.
MORE►
